Outsourcing, Venture

Clinical trial disruptor Science 37 in talks with SoftBank on a $150M investment — Recode

Just a few months after pharma giant Novartis partnered up with Science 37 on its virtual approach to clinical trial work, Recode reports that the would-be CRO disruptor is in talks with SoftBank execs on a $150 million investment.

Noah Craft, Science 37 CEO

SoftBank, which provided Roivant chief Vivek Ramaswamy with more than a billion dollars to invest in biotech, evidently has been drawn to Science 37’s promise that it can efficiently and effectively recruit patients for clinical trials without forcing them into a trial site. Using new telemedicine tech, they say they can accumulate clean datasets to show whether or not new drugs are working — hoping to disrupt the big players who now dominate the CRO world.

Quoting sources, Recode notes that Science 37 is planning to value itself at $300 million for this deal, up about $100 million since Lux Capital and Google’s GV helped back the company a little more than a year ago. 

SoftBank’s big, $98 billion Vision Fund has made repeated forays into the world of drug development and technology. Aside from Roivant, the group participated in the massive $500 million round to back George Scangos’ Vir, which is working on an infectious disease drug pipeline.

The CRO business has undergone a decade of shaking out as private equity groups moved in to buy up the outsourcing companies and meld them into a set of large and aggressive global players, often with big staffs. Shaking them up with a new tech approach won’t come easily in an R&D world where safe and dependable are key watchwords in the high-risk world of drug development.

But Science 37 continues to build up a head of steam to give it a try.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 41,800+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Head of Business Development
Wren Therapeutics Boston, MA
Life Sciences Venture Professional
Northpond Ventures Washington, DC
Senior Drug Discovery Oncologist
Schrödinger New York, NY

Visit Endpoints Careers ->